SCHEMBL20180713

SCHEMBL20180713

CNC(=O)CCC1(C)NN1

nearest known ligand 0.43

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
MCL1 Q07820 1/20 0.33
POLB P06746 1/20 0.33
KDM4E B2RXH2 1/20 0.32
KDM5C P41229 1/20 0.32
EGLN1 Q9GZT9 1/20 0.32
PHF8 Q9UPP1 1/20 0.32
KDM2A Q9Y2K7 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17835158 0.78
SCHEMBL17319497 0.73
SCHEMBL18925533 0.73 LMNA (0.43) LMNAMCL1POLBKDM4EKDM5C
SCHEMBL3660629 0.71 LMNA (0.63) LMNAMCL1POLBKDM4EKDM5C
SCHEMBL16579442 0.69 CASP2 (0.43) KDM4EALDH1A1
SCHEMBL23948507 0.68 LMNA (0.39) LMNAMCL1POLBTDP1
SCHEMBL8689460 0.68 LMNA (0.39) LMNAMCL1POLBTDP1ALDH1A1
SCHEMBL20708377 0.68 LMNA (0.39) LMNAMCL1POLBKDM4ETDP1
SCHEMBL21788681 0.67 FTO (0.38) LMNAMCL1
SCHEMBL93970 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11767294-B2 Conjugates of cell binding molecules with cytotoxic agents HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-09-26 US disclosed
US-10327423-B2 Antimicrobial compounds and compositions, and uses thereof Akeso Biomedical, Inc. (US) 2019-06-25 US disclosed
US-10264766-B2 Antimicrobial compounds and compositions, and uses thereof Akeso Biomedical, Inc. (US) 2019-04-23 US disclosed
US-20180139932-A1 ANTIMICROBIAL COMPOUNDS AND COMPOSITIONS, AND USES THEREOF Akeso Biomedical, Inc. 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180139932-A1 ANTIMICROBIAL COMPOUNDS AND COMPOSITIONS, AND USES THEREOF TYR, TH, DDC LMNA 4847/4885MCL1 2140/4885POLB 1637/4885
US-10264766-B2 Antimicrobial compounds and compositions, and uses thereof TYR, TH, DDC LMNA 4843/4885MCL1 2134/4885POLB 1663/4885
US-11767294-B2 Conjugates of cell binding molecules with cytotoxic agents CD4, CD2, CD47 LMNA 2180/4885MCL1 36/4885POLB 3755/4885
US-10327423-B2 Antimicrobial compounds and compositions, and uses thereof TYR, TH, DDC LMNA 4843/4885MCL1 2134/4885POLB 1663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.